Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Deals & M&A

Richter agrees AUD 604m takeover of Mayne Pharma at near-100% premium

Gedeon Richter will pay cash for the ASX-listed company, adding its US women's health and dermatology products, subject to a sale of Mayne's International arm to Evaris Pharma.

16 Nov 2026 · Gedeon Richter · Company news

Gedeon Richter has agreed to buy Mayne Pharma outright for AUD 6.40 a share in cash, a price that values the ASX-listed company at about AUD 604 million. The companies announced the agreement on 16 November 2026. The offer is roughly 99% above Mayne's last closing price, so shareholders are being offered close to double the prior market value.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Deals & M&AAll →